This blog is aimed to provide readers with the recent regulatory updates mainly from the China National Medical Products Administration (NMPA, formerly known as China Food and Drug Administration (CFDA)), as well as how these changes will impact the market access for international food, drug, and medical device companies in the world’s fastest growing consumer market – People’s Republic of China.

The lead author of this blog is Xin Tao, whose background in life science assists him in his science-based food and drug law practices. Born and raised in China, and trained in the US first as a research biochemist and then as a life science regulatory attorney, Xin’s unique ability in understanding and interpreting the complex scientific issues as they relate to the governing Chinese regulatory requirements and the cultural nuances when dealing with the Chinese authorities helps clients with all phases of the product development, manufacturing, and marketing in China.  Xin routinely serves as the China regulatory counsel during cross-border transactions and litigations, and he also has substantial experience in advising clients during high-stake enforcement actions initiated by NMPA.

Xin is a frequent speaker and contributor to industry publications both in the U.S. and China.  Xin is based in Washington DC and travels frequently to Beijing and Shanghai.

Xin lives in Potomac, Maryland with his wife and their three lovely children.  Xin is a history buff on Chinese ceramics and porcelain trade with Europe in the 17th century and an amateur collector of Chinese export porcelain of that period.

Xin Tao, Esq